RxDoctor Payments Data

Neelum Aggarwal

Neurology · Chicago, ILNPI 1154450799

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,492 of the $4,637 with a category attached, or 96.9%. Biogen accounts for 96.9% of it on its own, with 1 other manufacturer making up the rest.

$4,637in general payments, 2019–2025

Across 3 payments — averaging $1545.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$4K
  • Eisai Inc.$146
$944,971in research payments, 2019–2025

Across 82 payments — averaging $11,524 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eisai Inc.$454K
  • Eli Lilly$248K
  • Novartis$230K
  • Janssen Research & Development, LLC$9K
  • Biogen$4K

What the payments were for

  • Consulting fees$4,49297%
  • Food & beverage$1463%

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen1$4,492
Eisai Inc.2$146

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,637 in reported general payments places this provider in the 70th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Other neurology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →